About Arialys
Arialys is a Healthcare company based in La Jolla (United States) founded in 2021. Precision medicines for autoimmune neuropsychiatric diseases are developed. Arialys has raised $72.8 million across 2 funding rounds from investors including ARE, Avalon Bio Ventures and Catalys Pacific. Its chief executive, as recorded, is Peter Flynn. Arialys offers products and services including ART5803. Its focus areas include Services for Healthcare Providers and Medical Information Providers.
Company details
Arialys was established in 2021 in La Jolla, United States, as a private biotech company. Focus is placed on the development of precision medicines targeting autoimmune neuropsychiatric diseases. Scientific advancements in this sector are investigated to support therapeutic interventions for individuals impacted by these conditions. Operations center on research and innovation within the biotechnology field.
- Headquarters La Jolla, United States
- SectorsHealthcare
- Email••••••••
- Website arialysrx.com
- Social LinkedIn
- Total Equity Funding$72.8M (USD)
in 2 rounds
- Latest Funding Round$14.8M (USD), Seed
Jun 2025
- InvestorsARE
& 4 more
Products & Services of Arialys
Arialys offers a comprehensive portfolio of products and services, including ART5803.
Antibody that blocks autoantibodies to treat anti-NMDA receptor encephalitis.
Funding Insights of Arialys
Arialys has successfully raised a total of $72.8M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $14.8 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $72.8M
- Total Rounds 2
- Last Round Seed — $14.8M
- First Round $58M
(Sep 2023)
- Investors Count 5
All 2 funding rounds of Arialys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $14.8M | Seed | – | – | – |
| Sep 2023 | $58M | Seed | – | Avalon Bio Ventures, Catalys Pacific | – |
5 investors in total: 5 institutional.
Investors in Arialys
Arialys has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Avalon Bio Ventures and Catalys Pacific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| avalonbioventures.com | ||||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Invests in biotech companies via global networks and partnerships for disease treatments. | 2019 | catalyspacific.com | Cayman Islands | |
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States |
Investor details for Arialys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Arialys
2 people are tracked at Arialys (2 in leadership).
| Name | Role | Group |
|---|---|---|
Peter Flynn | CEO & President | Leadership |
Jay Lichter | CEO | Leadership |
Complete people profiles for Arialys
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Arialys
3 dated milestones of Arialys across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Arialys is founded.
- Funding First funding round of $58.0M.
- Funding Latest funding round, Seed, of $14.8M.
Top companies in Healthcare Provider Support Services
3 companies that operate in the same segment as Arialys (Healthcare Provider Support Services) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of self funded health plan | 2017 | New York, New York, United States | USD 224 M | 212 | ||
Provider of AI solutions for clinical, operational, and business outcomes | 2005 | Princeton, New Jersey, United States | USD 1.13 B | USD 465.22 M | 5,442 | |
AMN Healthcare is recognized as a leading healthcare staffing provider. | 1985 | San Diego, California, United States | USD 2.73 B | 2,970 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arialys
Complete news archive for Arialys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arialys
Arialys was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Arialys is headquartered in La Jolla, United States. It is registered at La Jolla, California, United States.
Peter Flynn is the CEO of Arialys, as recorded in our data.
Arialys is a funded company, having raised a total of $72.8M across 2 funding rounds to date. The company's 1st funding round was a Seed of $58M, raised on Sep 2023.
Arialys was established in 2021 in La Jolla, United States, as a private biotech company. Focus is placed on the development of precision medicines targeting autoimmune neuropsychiatric diseases. Scientific advancements in this sector are investigated to support therapeutic interventions for individuals impacted by these conditions. Operations center on research and innovation within the biotechnology field.
Arialys offers ART5803.
Arialys has 5 investors. Key investors include ARE, Avalon Bio Ventures, Catalys Pacific, Turmeric Acquisition Corp, and Johnson & Johnson Innovation – JJDC.